Crestovo

What Crestovo does

Crestovo is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts, that develops Full-Spectrum Microbiota therapeutic products designed to harness the human gut microbiome. Its core platform is built on insights from human microbiota transplantation studies, with the goal of producing standardized, clinically deployable microbiome-based interventions. The company operates in the microbial transplantation therapeutic space, serving healthcare and clinical institutions as its primary downstream customer segment.

As a clinical-stage entity, Crestovo's business model centers on biopharmaceutical research and development rather than commercial product sales, with no approved products or disclosed revenue. The broader addressable market for microbial transplantation kits is projected to reach USD 891.8 million by 2035, supported by clinical adoption trends, technological innovation in diagnostics, and ongoing regulatory activity. However, no Crestovo-specific pricing, partnership, distribution, or commercialization details are available in the input.

Crestovo's operational trajectory is closely tied to that of the successor microbiome entity (Finch Therapeutics), which discontinued its Phase 3 CP101 trial for recurrent C. difficile in January 2023, delisted from Nasdaq and completed SEC deregistration in October 2024, and as of early 2025 is focused on realizing value from its IP estate rather than advancing clinical programs. A January 2025 CFO resignation further signals organizational contraction. Specific Crestovo-branded operating status, leadership, pipeline, and pipeline-stage information is not available in the provided data.

Name

Crestovo

Legal name

Finch Therapeutics Group, Inc.

Website

https://crestovo.com

Company type

Public

Founded year

2016

Operating status

Operating

Short description

Crestovo is a clinical-stage biopharmaceutical company founded in 2014 in Cambridge, MA, developing Full-Spectrum Microbiota therapeutics derived from the human gut microbiome for clinical applications. Its operational trajectory is intertwined with successor entity Finch Therapeutics, which is in wind-down/IP-realization mode after a Phase 3 failure and Nasdaq delisting.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000)

akta.pro primary industry

Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products (HLAAAFAE)

akta.pro secondary industry

Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)

Keywords

• Microbiome therapeutics
• Full-Spectrum Microbiota
• Clinical-stage biopharmaceuticals
• Gut microbiome drugs
• Microbial transplantation

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota, a therapeutic approach that harnesses the human gut microbiome for clinical applications. The company focuses on creating standardized, regulated microbial transplantation solutions using defined microbial consortia. Its pipeline targets therapeutic use of microbiota in clinical settings, addressing the need for standardized microbial transplantation kits within healthcare.

Differentiator

Problem solved

Functional benefit

Products and services

• Full-Spectrum Microbiota

Quantifiable outcome

• Market growth to USD 891.8 million by 2035

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Emerging players

• MaaT Pharma: MaaT Pharma is a European clinical-stage microbiome therapeutics company developing standardized FMT-derived products for acute and chronic indications, including C. difficile and oncology support. Comparable platform model with narrower commercial reach.
• BiomX: BiomX develops engineered phage and microbiome-based therapeutics, focused on GI and skin indications. Adjacent modality in the broader microbiome therapeutics category.
• Second Genome: Second Genome is a clinical-stage microbiome drug discovery company engineering protein therapeutics and small molecules identified through microbiome research, partially comparable in platform approach and customer base.
• Evelo Biosciences: Evelo develops single-strain microbiome therapeutics for inflammatory and immunology indications, representing an adjacent but partially overlapping therapeutic-area peer in the microbiome modality.

Direct peers

• Rebiotix (Ferring Pharmaceuticals): Rebiotix developed Rebyota, an approved FMT-based product for recurrent C. difficile now commercialized by Ferring. It is the closest commercial-stage analog to Crestovo's full-spectrum microbiota approach.
• Seres Therapeutics: Seres was a leading microbiome therapeutics company (VOWST for recurrent C. difficile) targeting identical indications with defined consortia approaches. It represents the most direct competitive comparator to Crestovo's full-spectrum microbiota strategy.
• Vedanta Biosciences: Vedanta develops defined bacterial consortia for GI and infectious disease indications, including C. difficile. Same disease targets, same regulatory pathway, same customer base of clinical institutions and healthcare providers.
• Finch Therapeutics: Finch acquired Crestovo's assets and developed CP101, the rebranded Full-Spectrum Microbiota product. It is the most direct peer because the successor entity literally operates from Crestovo's clinical foundation.

Broad incumbents

• Assembly Biosciences: Assembly Bio has explored microbiome-based approaches alongside its core virology portfolio. Broad biotech with partial product overlap relevant to investors comparing alternative microbiome exposure.

Regional players

• 4D Pharma: 4D Pharma was a UK-based clinical-stage microbiome company developing single-strain and consortium Live Biotherapeutic Products for GI and oncology indications. Comparable platform, with primary geographic presence in Europe.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crestovo